What's Next: Orforglipron (oral GLP-1) completing Phase 3 trials with submissions expected by year-end 2025 CEO Dave Ricks expects FDA approval by March 2026 International launches accelerating in China, Brazil, India, and Mexico The GLP-1 market is projected to exceed $100B+ by the early 2030s, and Lilly is positioned as the category leader
The original container helps protect the tablets, so do not move them into a pill organizer unless a pharmacist or clinician says it is acceptable
Intestinal barrier function
It is often referred to as the body's "master antioxidant" due to its powerful ability to combat oxidative stress
Without enough methyl groups, estradiol and its metabolites (which still have estrogenic activity) will remain elevated
Over time, its also been studied for its potential effects on: Stress regulation Cortisol levels Pain perception Withdrawal symptoms That last point is whats driving interest in addiction and recovery spaces today